Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2016

GlobalData
323 Pages - GLDATA57839
$2,500.00

Summary

GlobalData's clinical trial report, “Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2016" provides an overview of Irritable Bowel Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Irritable Bowel Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

GlaxoSmithKline Plc
Novartis AG
Astellas Pharma Inc
Allergan Plc
Ironwood Pharmaceuticals Inc
Ardelyx Inc
Valeant Pharmaceuticals International Inc
Takeda Pharmaceutical Company Ltd
Sucampo Pharmaceuticals Inc
ICON Plc

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Irritable Bowel Syndrome Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Irritable Bowel Syndrome 30
Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 30
Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting 31
Oct 17, 2016: Final Results Of Real-World Data From Surveillance Study Confirm High Levels Of Patient Satisfaction And Rapid Irritable Bowel Syndrome Symptom Improvement With Non-Prescription IBgard 31
Oct 17, 2016: Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology Annual Scientific Meeting 32
Oct 17, 2016: Pregabalin may lessen pain from irritable bowel syndrome, Mayo Clinic study finds 33
Sep 28, 2016: Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program 33
Sep 27, 2016: Continuing Developments In Medical Consensus On The Utility Of Peppermint Oil For Irritable Bowel Syndrome 34
Clinical Trial Profile Snapshots 36
Appendix 320
Abbreviations 320
Definitions 320
Research Methodology 321
Secondary Research 321
About GlobalData 322
Contact Us 322
Disclaimer 322
Source 323

List of Tables
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region, 2016* 6
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 14
Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 17
Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 14
Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 17
Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 321

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports